Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...

B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up ...

and movement measures in patients with dementia with Lewy bodies (DLB). “The results from this exploratory Phase 2 trial demonstrated CT1812 could have a meaningful, positive impact on DLB ...

Dementia with Lewy bodies is the second most common cause of dementia, affecting an estimated 1.4 million Americans. The disease is believed to be caused by a buildup of the protein α-synuclein ...

Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body ...

Dementia with Lewy bodies is the second most common cause of dementia, affecting an estimated 1.4 million Americans. The disease is believed to be caused by a buildup of the protein a-synuclein, which ...